Saturday, June 17, 2017 4:18:30 PM
AHUS and Igan are no large scale phase 3's
Maiby 40 patients or so due to rare disease,the U.S.,Euro and Asia market value for IgA nephropathy is +$5B
At the ERA-EDTA meeting in Mardrid last week European & Asian institutions asked Omeros to participate in the phase 3 trial, so worldwide partnerships are already beeing forged. Next in pipeline is Immunotherapy and their addiction program, if they , in time , need to dilute for those it would be few 100k shares,They don't need that much. OMS527 would be phase 1. Those are cheap. And by then price could be 50 to 75
After phase 1 revenue will be sufficient to fund the rest of the trials
Yesterday was a shareholders meeting, not a CC , so imo no transcripts or replay
Over 90% of the outstanding shares were represented at the meeting
Quote from someone who was there
"Meeting was insanely positive. FDA basically begged them to go fast track for IGAN. Also, removed criteria that would make it take 2-3yrs for drug to market. Could be on market in a year. With 150k potential patients in US, cost of 70-100k per patient annually. Addiction drug potential unreal. Would be largest drug ever to come to market, 1-2 years aways from trials. 906 for arthritis scaling up for clinical trials. DR D believes recognition of OMER only beginning, wanted to be biggest pharma out of NW ever, thinks that now is conservative."
We also reached $1B market cap, the minimum m. Cap for some large institutions before they start buying,also 20% still shorted, if price continue to climb we will see a few squeezes in the proces
So to scale things up,2 five billion dollar products about to be launched between year end and half 2018 , start of Immunotherapy and 906 trials very soon and start trials for the MASSIVE OMS527 next year will make this a multi year runner
Addiction drug potential is beyond believe,Would be largest drug ever to come to market, pre trials were promising
$1000 company within 5 year
Sorry for the gramatical errors, i'm flemmish
Gltu
Recent OMER News
- Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results • Business Wire • 04/01/2024 08:02:00 PM
- Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024 • Business Wire • 03/27/2024 12:30:00 PM
- Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy • Business Wire • 02/20/2024 02:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:05:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:00:23 PM
- Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust • Business Wire • 02/01/2024 02:11:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/29/2024 08:26:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 01:11:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2023 02:46:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/16/2023 02:55:18 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:06:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:05:36 PM
- Omeros Corporation Reports Third Quarter 2023 Financial Results • Business Wire • 11/09/2023 09:02:00 PM
- Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023 • Business Wire • 11/06/2023 01:00:00 PM
- Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy • Business Wire • 11/03/2023 01:05:00 PM
- Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting • Business Wire • 11/02/2023 01:05:00 PM
- Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer • Business Wire • 10/19/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 08:36:07 PM
- Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy • Business Wire • 10/16/2023 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2023 09:02:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2023 08:56:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2023 08:53:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/20/2023 08:47:29 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM